http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 견진옥 ( Jin Ok Kyun ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
만성 B 형 바이러스성 간염환자에서 lamivudine 52 주 투여의 치료효과에 대한 연구
견진옥(Jin Ok Kyun),오정미(Jung Mi Oh),조성원(Sung Won Cho) 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.2
Lamivudine, an oral nucleoside analogue, effectively inhibits hepatitis B virus replication and reduces hepatic necroinflammation in patients with chronic hepatitis B. Although lamivudine has shown a promise in patients with chronic hepatitis B, a long-term data on Korean patients with hepatitis B are lacking. The purpose of this study is to evaluate the effects and safety of 52-week lamivudine therapy in Korean patients with chronic hepatitis B. A total of twenty-nine patients (27 male and 2 female) who had received 100 mg of oral lamivudine daily for 52 weeks were evaluated, retrospectively. The mean age of 29 patients in the study group was 37.7±8.9 years (range 19-54). Pretreatment HBV PCR and HBsAg were positive in all 29 patients, and HBeAg were positive in 25 patients (86%). The serum HBV DNA of 28 patients (97%) significantly fell to undetectable levels (<5 pg/ml) within 12 weeks of therapy and it remained undetectable in 24 patients (83%) by the end of 52-week therapy (p<0.001). Mean serum ALT levels of 29 patients declined to the normal range within 12 weeks and remained within the normal range during the evaluative period (p<0.05). The proportions of patients with HBeAg seroconversion (loss of HBeAg, development of antibody to HBeAg, and undetectable HBV DNA) were 42% after 52-week therapy. The differences of response to lamivudine therapy in HBeAg-positive and HBeAg-negative patients were negligible (p>0.05). Furthermore, the study showed that pretreatment serum HBV DNA and ALT levels have no effect to the efficacy of lamivudine therapy (p>0.05). Further comparison of lamivudine`s efficacy showed that lamivudine is just as efficacious in patients with cirrhosis as without cirrhosis (p>0.05). In conclusion, lamivudine is an effective and safe therapy for the treatment of chronic hepatitis B in Korean patients.
-
김정은 ( Jeong Eun Kim ),견진옥 ( Jin Ok Kyun ),진선민 ( Sun Min Jin ),이영희 ( Young Hee Lee ),김주희 ( Joo Hee Kim ),이현영 ( Hyun Young Lee ),박해심 ( Hae Sim Park ),최영화 ( Young Wha Choi ),예영민 ( Young Min Ye ) 대한천식알레르기학회 2010 천식 및 알레르기 Vol.30 No.3
Background: There have been few reports on the characteristics of adverse drug reactions (ADRs) in elderly patients among the Korean population. Objective: To investigate the characteristics of ADRs in elderly patients compared with those in younger ones. Method: ADRs were collected from a spontaneous reporting system at our university hospital in 2008. Characteristics including underlying diseases, duration of hospitalization, clinical manifestations, culprit drugs and number of concomitant medications were compared between the young (<65 years) and elderly (≥65 years) groups. Result: A total of 528 ADRs occurred in 513 patients, and 120 ADRs (22.7%) occurred in 116 elderly patients. Their mean age was 71.6 years. Antibiotics (45.8%) were the most common culprit drugs. The prevalence of ADRs due to cardiovascular drugs was significantly higher in the elderly group (9.2%) than in the young group (2.9%, P=0.003). The most prevalent clinical types were skin manifestations (40.5%), gastrointestinal abnormalities (28.4%) and systemic reactions (23.5%) in both groups. Renal function abnormalities were significantly more prevalent in the elderly group (4.2%) than in the young group (0.5%, P=0.008). The mean number of concomitant medications was significantly higher in the elderly group (6.5±4.6) than in the young group (1.9±3.9). Conclusion: For the early detection of ADRs in elderly patients, close monitoring of cardiovascular drug use and renal function are recommended. (Korean J Asthma Allergy Clin Immunol 2010;30:216-221)
ScienceON
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
